Nonlinear kinetics after high-dose omeprazole caused by saturation of genetically variable CYP2C19

Hepatology

Volumn 23, Issue 6, 1996, Pages 1491-1497

  Rost, Karl Ludwig ^a   Roots, Ivar ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b HUMBOLDT UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; OMEPRAZOLE; OMEPRAZOLE DERIVATIVE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISPOSITION; DRUG MEGADOSE; DRUG METABOLISM; ENZYME ACTIVITY; FEMALE; GENETIC VARIABILITY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PLASMA CLEARANCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

EID: 0029982257     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.1996.v23.pm0008675169     Document Type: Article

References (13)

1. Smallwood RA, Berlin RG, Castagnoli N, Festen HPM, Hawkey CJ, Lam SK, Langman MJS, et al. Safety of acid-suppressing drugs. Dig Dis Sci 1995;40:63S-80S.
2. Wilde MI, McTavish D. Omeprazole. An update of its pharmacology and therapeutic use in acid-related disorders. Drugs 1994;48:91-132.
3. Lamberts R, Creutzfeldt W, Strüber HG, Brunner G, Solcia E. Long-term omeprazole therapy in peptic ulcer disease: gastrin, endocrin cell growth, and gastritis. Gastroenterology 1993;104-1356-1370.
4. Jensen RT, Fraker DL. Zollinger-Ellison syndrome. Advances in treatment of gastric hypersecretion and the gastrinoma. JAMA 1994;271:1429-1435.
5. Metz DC, Strader DB, Orbuch M, Koviack PD, Feigenbaum KM, Jensen RT. Use of omeprazole in Zollinger-Ellison syndrome: a prospective nine-year study of efficacy and safety. Aliment Pharmacol Ther 1993;7:597-610.
6. Bayerdörffer E, Miehlke S, Mannes GA, Sommer A, Hochter W, Weingart J, Heldwein W, et al. Double-blind trial of omeprazole and amoxicillin to cure Helicobacter pylori infections in patients with duodenal ulcers. Gastroenterology 1995;108:1412-1417.
7. Andersson T, Andrén K, Cederberg C, Lagerström PO, Lundborg P, Skånberg I. Pharmacokinetics and bioavailability of omeprazole after single and repeated oral administration in healthy subjects. Br J Clin Pharmacol 1990;29:557-563.
8. Andersson T, Regårdh C-G, Lou Y-C, Zhang Y, Dahl M-L, Bertilsson L. Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects. Pharmacogenetics 1992;2:25-31.
9. Regårdh C-G, Andersson T, Lagerström, Lundborg P, Skånberg I. The pharmacokinetics of omeprazole in humans - a study of single intravenous and oral doses. Ther Drug Monit 1990;12:163-172.
10. Sohn D-R, Kobayashi K, Chiba K, Lee K-H, Shin S-G, Ishizaki T. Disposition kinetics and metabolism of omeprazole in extensive and poor metabolizers of S-mephenytoin 4′-hydroxylation recruited from an oriental population. J Pharm Exp Ther 1992;262:1195-1202.
11. Vinayek R, Amantea MA, Maton PN, Frucht H, Gardner JD, Jensen RT. Pharmacokinetics of oral and intravenous omeprazole in patients with the Zollinger-Ellison syndrome. Gastroenterology 1991;101:138-147.
12. Ching MS, Mihaly GW, Angus PW, Morgan DJ, DevenishMearcs S, Yeomans ND, Smallwood RA. Oral bioavailability of omeprazole before and after chronic therapy in patients with duodenal ulcer. Br J Clin Pharmacol 1991;31:166-170.
13. Howden CW, Meredith PA, Forrest JAH, Reid JL. Oral pharmacokinetics of omeprazole. Eur J Clin Pharmacol 1984;26:641-643.